DOLF Sponsored

Impact of annual and semi-annual mass drug administration for Lymphatic Filariasis and Onchocerciasis on Hookworm Infection in Cote d’Ivoire
Loukouri A, Meite A, Koudou BG, Goss CW, Lew D, Weil GJ, N’Goran EK, Fischer PU
PLoS Negl Trop Dis. 2020;14(9):e0008642.

Single-Dose Triple-Drug Therapy for Wuchereria bancrofti — 5-Year Follow-up
King C , Weil GJ, Kazura JW
N Engl J Med. 2020;382(20):1956-1957

Comparison of repeated doses of ivermectin versus ivermectin plus albendazole for the treatment of onchocerciasis: A randomized, open-label, clinical trial
Batsa Debrah L, Klarmann-Schultz U, Osei-Mensa J, Dubben B, Fischer K, Mubarik Y, Ayisi-Boateng MK, Ricchiuto A, Fimmers R, Kanadu P, Nadal J, Gruetzmacher B, Weil G,  Kazura JW, King CL, Debrah AY, Hoerauf A
Clin Infect Dis. 2020;71:933-943

Efficacy and safety of a single dose of ivermectin, diethylcarbamazine and albendazole for treatment of lymphatic filariasis in Cote d’Ivoire: an open-label, randomized, controlled trial
Bjerum CM, Ouattara AF, Meite A, Kouadio O, Marius VK, Andersen B, Weil GJ, Koudou BG, King CL
Clin Infect Dis. 2019; in press

Frequency and clinical significance of localized adverse events following mass drug administration for lymphatic filariasis in an endemic area in South India
Kuttiatt VS, Somani RK, Swaminathan S, Krishnamoorthy K, Weil GJ, Purushothaman J
Am J Trop Med Hyg. 2019;102(1):96-99

Systems analysis-based assessment of post-treatment adverse events in lymphatic filariasis
Andersen BJ, Rosa BA, Kupritz J, Meite A, Serge T, Hertz MI, Curtis K, King CL, Mitreva M, Fischer PU, Weil GJ
PLoS Negl Trop Dis. 2019;13(9):e0007697

Systematic sampling of adults as a sensitive means of detecting persistence of lymphatic filariasis following mass drug administration in Sri Lanka
Rao RU, Samarasekera SD, Nagodavithana KC, Puhchihewa MW, Ranasinghe USB, Weil GJ
PLoS Negl Trop Dis. 2019;13(4):e0007365

Pharmacokinetics, safety, and efficacy of a single co-administered dose of diethylcarbamazine, albendazole and ivermectin in adults with and without Wuchereria bancrofti infection in Côte d’Ivoire
Edi C, Bjerum CM, Koudou BG, Chhonker YS, Penali LK, Meite S, Ouattara AF, Weil GJ, King CL, Murry DJ
PLoS Negl Trop Dis. 2019;13(5):e0007325

The safety of double-and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study
Weil GJ, Bogus J, Christian M, Dubray C, Djuardi Y , Fischer PU, Goss CW, Hardy M, Jambulingam P, King CL, Kuttiat VS,  Krishnamoorthy K, Laman M, Lemoine, JF, OBrian KK, Robinson LJ, Samuela J, Schechtman KB, Sircar A, Srividya A, Steer AC, Supali T, Subramanian S, The DOLF IDA Safety Study Group
PLoS Negl Trop Dis. 2019;16(6):e1002839

Dosing pole recommendations for lymphatic filariasis elimination: a height-weight quantile regression modeling approach
Goss CW, O’Brian K, Dubray C, Fischer PU, Hardy M, Jambulingam P, King CL, Laman M, Lemoine JF, Robinson L, Sameula J, Swaminathan S, Supali T, Weil GJ, Schechtman KB
PLoS Negl Trop Dis. 2019;13(7):e0007541

Risk factors for lymphatic filariasis in two villages of the Democratic Republic of the Congo
Chenais CB, Awaca-Uvon NP, Vlaminck J, Tambwe JP, Weil GJ, Pion SD, Boussinesq M
Parasit Vectors. 2019;12:162

Comparison of the impact of annual and semiannual mass drug administration on lymphatic filariasis prevalence in Flores Island, Indonesia
Supali T, Djuardi Y, Lomiga A,  Linda SN, Iskander E, Goss CW, Miller JP, Weil GJ, Fischer PU
Am J Trop Med Hyg. 2019;100(2):336-343

A trial of a triple-drug treatment for lymphatic filariasis
King CL, Suamani J, Sanuku N, Cheng YC, Satofan S, Mancuso B, Goss CW, Robinson LJ, Siba PM, Weil GJ, Kazura JW
N Engl J Med. 2018;379(19):1801-1810

 Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature
Budge PJ, Herbert C, Andersen BJ, Weil GJ
PLoS Negl Trop Dis. 2018;12(5):e0006454

Capillaria ova and Diagnosis of trichuris trichiura Infection in humans by kato-katz smear, Liberia
Fischer K, Gankpala A, Gankpala L, Bolay FK, Curtis KC, Weil GJ, Fischer PU
Emerg Infect Dis. 2018;24(8):1551-1554

Identification and characterization of Loa loa antigens responsible for cross-reactivity with rapid diagnostic tests for lymphatic filariasis
Hertz MI, Nana-Djeunga H, Kamgno J, Jelil Njouendou A, Chawa Chunda V, Wanji S, Budge PJ
PLoS Negl Trop Dis. 2018;12(11):e0006963

Update on the current status of onchocerciasis in Cote d’Ivoire following 40 years of intervention: Progress and challenges
Koudou BG, Kouakou MM, Ouattara AF, Yeo S, Brika P, Meite A, Fischer PU
PLoS Negl Trop Dis. 2018;12(10):e0006897

Comprehensive assessment of a hotspot with persistent bancroftian filariasis in coastal Sri Lanka
Rao RU, Samarasekera SD, Nagodavithana KC, Dassanayaka TDM, Punchihewa MW, Ranasinghe USB, Weil GJ
Am J Trop Med Hyg. 2018;99(3):735-742

Changes in cytokine, filarial antigen, and DNA levels associated with adverse events following treatment of lymphatic filariasis
Andersen BJ, Kumar J, Curtis K, Sanuku N, Satafan S, King CL, Fischer PU, Weil GJ
J Infec Dis. 2018;217(2): 280- 287

Differential human gut microbiome assemblages during soil-transmitted helminth infections in Indonesia and Liberia
Rosa BA, Supali T, Gankpala L, Djuardi Y, Sartono E, Zhou Y, Fischer K, Martin J, Tyagi R, Bolay FK, Fischer PU, Yazdanbakhsh M, Mitreva M
Microbiome. 2018;6:33

Reassessment of areas with persistent lymphatic filariasis nine years after cessation of mass drug administration in Sri Lanka
Rao RU, Samarasekera SD, Nagodavithana DC, Dassanayaka TDM, Punchihewa MW, Ranasinghe USB, Weil GJ
PLoS Negl Trop Dis. 2017;11(10):e0006066

A multi-center field study of two point-of-care tests for circulating Wuchereria bancrofti antigenemia in Africa
Chesnais CB, Awaca-Uvon NP, Bolay FK, Boussinesq M, Fischer PU, Gankpala L, Meite A, Missamou F, Pion SD, Weil GJ
PLoS Negl Trop Dis. 2017; 11(9):e0005703

Effect of 3 years of biannual mass drug administration with albendazole on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in Republic of the Congo
Pion SDS, Chesnais CB, Weil GJ, Fischer PU, Missamou F, Boussinesq M
Lancet Infect Dis. 2017;17(7):763-769

Potential value of triple Drug therapy with ivermectin, diethylcarbamazine, and albendazole (IDA) to accelerate elimination of lymphatic filariasis and onchocerciasis in Africa
Fischer PU, King CL, Jacobson JA, Weil GJ
PLoS Negl Trop Dis. 2017;11(1):e0005163

Use of a novel portable 3D scanner to measure limb volume and circumference in patients with filarial lymphedema
Yahathugoda C, Weiler M, Rao R, De Silva L, Dixon J, Weerasooriya M, Weil GJ, Budge P
Am J Trop Med Hyg. 2017;97(6):1836-1842

Effectiveness of a triple-drug Regimen for global elimination of lymphatic filariasis: A modelling study
Irvine MA, Stolk WA , Smith ME, Subramanian S, Singh BK, Weil GJ, Michael E, Hollingsworth TD
Lancet Infect Dis. 2016;17(4):451-458

Measurement of circulating filarial antigen levels in human blood with a point-of-care test strip and a portable spectrodensitometer
Chesnais CB , Vlaminck J , Kunyu-Shako B, Pion SD, Awaca-Uvon NP, Weil GJ, Mumba D, Boussinesq M 
Am J Trop Med Hyg. 2016;94(6):1324-1329

Familial aggregation and heritability of Wuchereria bancrofti infection
Chesnais CB , Sabbagh A , Pion SD,  Missamou F, Garcia A, Boussinesq MJ 
J Infect Dis. 2016;214:587-594

Programmatic use of molecular xenomonitoring at the level of evaluation units to assess persistence of lymphatic filariasis in Sri Lanka
Rao RU, Samarasekera SD , Nagadavithana KC , Punchilewa MW , Dassanayaka TDM , Gamini PKD, Ford E, Udaya S, Ranassinghe B, Henderson RH, Weil GJ 
PLoS Neglected Trop Dis. 2016;10(5):e0004722

Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis
Thomsen EK, Sanuku N, Baea M, Satofan S, Maki E, Lombore B, Schmidt MS,  Siba PM, Weil GJ, Kazura JW, Fleckenstein LL, King CL
Clin Infect Dis. 2016;62(3):334-41

Community attitudes toward mass drug administration for control and elimination of neglected tropical diseases after the 2014 outbreak of ebola virus disease in Lofa County, Liberia
Bogus J, Gankpala L, Fischer K, Krentel A, Weil GJ, Fischer PU, Kollie K, Bolay FK
Am J Trop Med Hyg. 2016;94(3):497-503

A Comparison of two tests for filarial antigenemia in areas in Sri Lanka and Indonesia with low-level persistence of lymphatic filariasis following mass drug administration
TC Yahathugoda, T Supali, RU Rao, Y Djuardi, D Stefani, F Pical, PU Fischer, MM Lloyd, PH Premaratne, MV Weerasooriya, GJ Weil
Parasit Vectors. 2015;8:369

The impact of two semi-annual treatments with Albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: A community-based study in the Republic of Congo
Pion SDS , Chesnais CB , Bopda J, Louya F, Fischer PU, Majewski AC, Weil GJ, Boussinesq M, Missamou F
Am J Trop Med Hyg. 2015;92(5):959-966

Conventional parasitology and DNA-based diagnostic methods for onchocerciasis elimination programmes
Lloyd MM, Gilbert R, Taha NT, Weil GJ, Meite A, Kouakou IMM, Fischer PU
Acta Trop. 2015;146:114-118

Diagnostic tools for onchocerciasis elimination programs
Vlaminck J, Fischer PU, Weil GJ
Trends Parasitol. 2015;31(11):571-82

Filarial antigenemia and Loa loa night blood microfilaremia in an area without bancroftian filariasis in the Democratic Republic of Congo
Bakajika DK, Nigo MM , Lotsima JP , Masikini GA , Fischer K , Lloyd MM , Weil GJ, Fischer PU
Am J Trop Med Hyg. 2014;91(6):1142-1148

A case study of risk factors for lymphatic filariasis in the Republic of Congo
Chesnais CB , Missamou F, Pion SD, Bopda J, Louya F, Majewski AC , Fischer PU, Weil GJ, Boussinesq M
Parasit Vectors. 2014;7:300

A comprehensive assessment of lymphatic filariasis in Sri Lanka six years after cessation of mass drug administration
Rao RU , Nagodavithana KC , Samarasekera SD , Wijegunawardana AD , Premakumara WDY , Perera SN , Settinayake S , Miller JP , Weil GJ
PLoS NTD. 2014;8(11):e3281

Liquid chromatography-mass spectrometry analysis of diethylcarbamazine in human plasma for clinical pharmacokinetic studies
Schmidt MS, King CL, Thomsen EK, Siba PM, Sanuku N, Fleckenstein L
J Pharm Biomed Anal. 2014;98:307-10

Exploring the potential of flubendazole in filariasis control: Evaluation of the systemic exposure for different pharmaceutical preparations
Ceballos L, Mackenzie C, Geary T,  Alvarez L, Lanusse C
PLoS Negl Trop. 2014;8(5):e2838

Integrated school-based surveillance for soil-transmitted helminth infections and lymphatic filariasis in Gampaha District, Sri Lanka
Gunawardena S, Gunawardena NK, Kahathuduwa G, Karunaweera ND, de Silva NR, Ranasinghe UB, Samarrasekara SD, Nagodavithana KC, Rao RU, Rebollo MP, Weil GJ
Am J Trop Med Hyg. 2014;90(4):661-666

Semi-quantitative scoring of an immunochromatographic test for circulating filarial antigen
Chesnais CB, Missamou F, Pion SDS , BopdaJ , F Louya, Majewski AC, Weil GJ, Boussinesq M
Am J Trop Med Hyg. 2013;89(5):916-918

A review of factors that influence individual compliance with mass drug administration for elimination of lymphatic filariasis
Krentel A, Fischer PU, Weil GJ
PLoS Negl Trop. 2013;7(11):e2447

Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood
Weil GJ, Curtis KC, Fakoli L, Fischer K, Gankpala L, Lammie PJ,  Majewski AC, Pelletreau S, Won KY, Bolay FK, Fischer PU
Am J Trop Med Hyg. 2013;89(1):11-15

Modeling the impact and costs of semiannual mass drug administration for accelerated elimination of lymphatic filariasis
Stolk WA, ten Bosch QA, de Vlas SJ, Fischer PU, Weil GJ, Goldman AS
PLoS Negl Trop. 2013;7(1):e1984

A review of flubendazole and its potential as a macrofilariacide
Mackenzie C
A report submitted to Dr. Gary Weil (PI DOLF) – a study supported by the Bill & Melinda Gates Foundation

Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs
Mackenzie CD,  Geary TG
Expert Rev Anti Infect Ther. 2011;9(5):497-501